Early markers of diabetic nephropathy


Цитировать

Полный текст

Аннотация

Диабетическая нефропатия (ДН) занимает одно из ведущих мест в современной структуре причин хронической почечной недостаточности. В статье обсуждаются общепризнанные и перспективные маркеры диабетического поражения почек, в том числе его ранних стадии

Об авторах

И А Бондарь

Кафедра эндокринологии Новосибирского государственного медицинского университета, Новосибирск

Кафедра эндокринологии Новосибирского государственного медицинского университета, Новосибирск

В В Климонтов

Кафедра эндокринологии Новосибирского государственного медицинского университета, Новосибирск

Кафедра эндокринологии Новосибирского государственного медицинского университета, Новосибирск

I A Bondar

V V Klimontov

Список литературы

  1. Дедов И.И., Викулова О.К., Сухарева О.Ю., Сунцов Ю.И. Скрининг диабетической нефропатии в Российской Федерации. В: Шестакова М.В., Дедов И.И. (ред.). Сахарный диабет и хроническая болезнь почек. М.: Медицинское информационное агентство. 2009. 39-59.
  2. Fioretto P., Caramori M.L., Mauer M. The kidneys in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia 2008; 51: 1051-1057.
  3. Бондарь И.А., Климонтов В.В. Функциональная морфология почек при сахарном диабете. В: Шестакова М.В., Дедов И.И. (ред.). Сахарный диабет и хроническая болезнь почек. М.: Медицинское информационное агентство. 2009. 149-176.
  4. Бондарь И.А., Климонтов В.В., Надеев А.П., Ким Л.Б. Экскреция гидроксипролина с мочой и локализация коллагенов III, IV и VI типа в клубочках почек у больных сахарным диабетом типа 1 с нефропатией. Пробл. эндокринол. 2005; 4: 6-10.
  5. Бондарь И.А., Климонтов В.В., Рогова И.П., Надеев А.П. Почки при сахарном диабете: патоморфология, патогенез, ранняя диагностика, лечение. Новосибирск: Изд-во НГТУ. 2008.
  6. Kobayashi T., Inoue T., Okada H. et al. Connective tissue growth factor mediates the profibrotic effects of transforming growth factor-beta produced by tubular epithelial cells in response to high glucose. Clin. Exp. Nephrol. 2005; 9: 114-121.
  7. Дедов И.И., Шестакова М.В. Сахарный диабет и артериальная гипертензия. М.: Медицинское информационное агентство, 2006.
  8. Fioretto P., Steffes M.W., Sutherland D.E. et al. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N. Engl. J. Med. 1998; 339: 69-75.
  9. Fioretto P., Sutherland D.E., Najafian B., Mauer M. Remodeling of renal interstitial and tubular lesions in pancreas transplant recipients. Kidney Int. 2006; 69: 907-912.
  10. Rossing P. The changing epidemiology of diabetic microangiopathy in type 1 diabetes. Diabetologia 2005; 48: 1439-1444.
  11. Viberti G.C., Wiseman M.J. The kidney in diabetes: significance of the early abnormalities. Clin. Endocrinol. Metab. 1986; 15: 753-782.
  12. Microalbuminuria Collaborative Study Group. Predictors of the development of microalbuminuria in patients with Type 1 diabetes mellitus: a seven-year prospective study. Diabet. Med. 1999; 16: 918-925.
  13. Rachmani R., Levi Z., Lidar M. et al. Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients. Diabetes Res. Clin. Pract. 2000; 49: 187-194.
  14. Stone M.L., Craig M.E., Chan A.K. et al. Natural history and risk factors for microalbuminuria in adolescents with type 1 diabetes: a longitudinal study. Diabetes Care 2006; 29: 2072-2077.
  15. Jerums G., Panagiotopoulos S., Maclsaac R.J. Diabetic nephropathy: epidemiology and clinical description. In: Boner G., Cooper M.E. (ed.). Management of Diabetic Nephropathy. London, N.-Y. 2003. P. 37-60.
  16. Svensson M., Sundkvist G., Arnqvist H.J. et al. Signs of nephropathy may occur early in young adults with diabetes despite modern diabetes management: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care. 2003; 26: 2903-2909.
  17. Raile K., Galler A., Hofer S. et al. Diabetic nephropathy in 27,805 children, adolescents, and adults with type 1 diabetes: effect of diabetes duration, A1C, hypertension, dyslipidemia, diabetes onset, and sex. Diabetes Care 2007; 30: 2523-2528.
  18. Marcovecchio M.L., Dalton R.N., Prevost A.T. et al. Prevalence of abnormal lipid profiles and the relationship with the development of microalbuminuria in adolescents with type 1 diabetes. Diabetes Care. 2009; 32: 658-663.
  19. Rossing P., Hougaard P., Parving H.H. Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study. Diabetes Care 2002; 25: 859-864.
  20. Grzegorz P., Krolewski A.S. Genetic determinants of diabetic nephropathy. In: Cortes P., Mogensen C.E. (eds). The diabetic kidney. Totowa, New Jersey: Humana Press. 2006. 329-350.
  21. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 4-е изд. Дедов И.И., Шестакова М.В. (ред.). М.: Медиа Сфера, 2009.
  22. Dalla Vestra M., Saller A., Bortoloso E. et al. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab. 2000; 26 (Suppl. 4): 8-14.
  23. Бондарь И.А., Климонтов В.В., Надеев А.П., Бгатова Н.П. Начальные изменения в почках у больных сахарным диабетом 1-го типа. Пробл. эндокринол. 2007; 5: 3-8.
  24. Mogensen C.E., Christensen C.K. Predicting diabetic nephropathy in insulin-dependent patients. N. Engl. J. Med. 1984; 311: 389-393.
  25. Viberti G.C., Wiseman M.J. The kidney in diabetes: significance of the early abnormalities. Clin. Endocrinol. Metab. 1986; 15: 753-782.
  26. Caramori M.L., Fioretto P., Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes. 2000; 49: 1399-1408.
  27. Perkins B.A., Ficociello L.H., Silva K.H. et al. Regression of microalbuminuria in type 1 diabetes. N. Engl. J. Med. 2003; 348: 2285-2293.
  28. Giorgino F., Laviola L., Cavallo Perin P. et al. Factors associated with progression to macroalbuminuria in microalbuminuric Type 1 diabetic patients: the EURODIAB Prospective Complications Study. Diabetologia. 2004; 47: 1020-1028.
  29. Newman D.J., Mattock M.B., Dawnay A.B. et al. Systematic review on urine albumin testing for early detection of diabetic complications. Health Technol. Assess. 2005; 9: iii-vi, xiii-163.
  30. Vilarrasa N., Soler J., Montanya E. Regression of microalbuminuria in type 1 diabetic patients: results of a sequential intervention with improved metabolic control and ACE inhibitors. Acta Diabetol. 2005; 42: 87-94.
  31. Gerstein H.C. Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE. Diabetes Metab. Res. Rev. 2002; 18, Suppl. 3: S82-S85.
  32. Valmadrid C.T., Klein R., Moss S.E., Klein B.E. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch. Intern. Med. 2000; 160: 1093-1100.
  33. Casiglia E., Zanette G., Mazza A. et al. Cardiovascular mortality in non-insulin-dependent diabetes mellitus. A controlled study among 683 diabetics and 683 age- and sex-matched normal subjects. Eur. J. Epidemiol. 2000; 16: 677-684.
  34. Torffvit O., Lövestam-Adrian M., Agardh E., Agardh C. D. Nephropathy, but not retinopathy, is associated with the development of heart disease in Type 1 diabetes: a 12-year observation study of 462 patients. Diabet. Med. 2005; 22 (6): 723-729.
  35. Groop P.H., Thomas M.C., Moran J.L. et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes. 2009; 58: 1651-1658.
  36. Rachmani R., Levi Z., Lidar M. et al. Considerations about the threshold value of microalbuminuria in patients with diabetes mellitus: lessons from an 8-year follow-up study of 599 patients. Diabetes Res. Clin. Pract. 2000; 49: 187-194.
  37. Schultz C.J., Neil N.A., Dalton N.R. et al. Risk of nephropathy can be detected before the onset of microalbuminuria during the early years after the diagnosis of type 1 diabetes. Diabetes Care 2000; 23: 1811-1815.
  38. Мухин Н. А., Фомин В. В., Моисеев С. В. Микроальбуминурия - универсальный маркер неблагоприятного прогноза. Клин. мед. 2008; 11: 4-9.
  39. Kotajima N., Kimura T., Kanda T. et al. Type IV collagen as an early marker for diabetic nephropathy in non-insulin-dependent diabetes mellitus. J. Diabetes Complications 2000; 14: 13-17.
  40. Okonogi H., Nishimura M., Utsunomiya Y. et al. Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus. Clin. Nephrol. 2001; 55: 357-364.
  41. Tashiro K., Koyanagi I., Ohara I., et al. Levels of urinary matrix metalloproteinase-9 (MMP-9) and renal injuries in patients with type 2 diabetic nephropathy. J. Clin. Lab. Anal. 2004; 18: 206-210.
  42. Thrailkill K.M., Bunn R.C., Moreau C.S. et al. Matrix metalloproteinase-2 dysregulation in type 1 diabetes. Diabetes Care 2007; 30: 2321-2326.
  43. Ebihara I., Nakamura T., Shimada N., Koide H. Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus. Am. J. Kidney Dis. 1998; 32: 544-550.
  44. Ishimura E., Nishizawa Y., Shoji S., Mori H. Serum type III, IV collagens and TIMP in patients with type II diabetes mellitus. Life Sci. 1996; 58: 1331-1337.
  45. Gambaro G., Cicerello E., Mastrosimone S. et al. High urinary excretion of glycosaminoglycans: a possible marker of glomerular involvement in diabetes. Metabolism. 1989; 38: 419-420.
  46. Juretić D., Krajnović V., Lukac-Bajalo J. Altered distribution of urinary glycosaminoglycans in diabetic subjects. Acta Diabetol. 2002; 39: 123-128.
  47. Korpinen E., Teppo A.M., Hukkanen L. et al. Urinary transforming growth factor-beta1 and alpha1-microglobulin in children and adolescents with type 1 diabetes. Diabetes Care 2000; 23: 664-668.
  48. Бондарь И.А., Климонтов В.В., Надeев А.П. Мочевая экскреция провоспалительных цитокинов и трансформирующего фактора роста β на ранних стадиях диабетической нефропатии. Тер. архив. 2008; 1: 52-56.
  49. Ohshiro Y., Ma R.C., Yasuda Y. et al. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice. Diabetes 2006; 55: 3112-3120.
  50. Chen S., Jim B., Ziyadeh F.N. Diabetic nephropathy and transforming growth factor-beta: transforming our view of glomerulosclerosis and fibrosis build-up. Semin. Nephrol. 2003; 23: 532-543.
  51. Matos J.P., de Lourdes Rodrigues M., Ismerim V.L. et al. Effects of dual blockade of the renin angiotensin system in hypertensive type 2 diabetic patients with nephropathy. Clin. Nephrol. 2005; 64: 180-189.
  52. Woo V., Ni L.S., Hak D. et al. Effects of losartan on urinary secretion of extracellular matrix and their modulators in type 2 diabetes mellitus patients with microalbuminuria. Clin. Invest. Med. 2006; 29: 365-372.
  53. Hellmich B., Schellner M., Schatz H., Pfeiffer A. Activation of transforming growth factor-beta1 in diabetic kidney disease. Metabolism 2000; 49: 353-359.
  54. Sharma K., Ziyadeh F.N., Alzahabi B. et al. Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997; 46: 854-859.
  55. Riser B.L., Fornoni A., Karoor S. Connective tissue growth factor in the pathogenesis of diabetic nephropathy: a target for therapeutic intervention. In: Cortes P., Mogensen C.E. (eds). The diabetic kidney. Totowa, New Jersey: Humana Press. 2006. 175-186.
  56. Tam F.W., Riser B.L., Meeran K. et al. Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine 2009; 47: 37-42.
  57. Nguyen T.Q., Tarnow L., Jorsal A. et al. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care 2008; 31: 1177-1182.
  58. Vasylyeva T.L., Ferry R.J.Jr. Novel roles of the IGF-IGFBP axis in etiopathophysiology of diabetic nephropathy. Diabetes Res. Clin. Pract. 2007; 76: 177-186.
  59. Cummings E.A., Sochett E.B., Dekker M.G. et al. Contribution of growth hormone and IGF-I to early diabetic nephropathy in type 1 diabetes. Diabetes 1998; 47: 1341-1346.
  60. Бондарь И.А., Климонтов В.В. Экскреция инсулиноподобного фактора роста 1 и фактора роста эндотелия сосудов с мочой у больных сахарным диабетом 1-го типа с нефропатией. Пробл. эндокринол. 2007; 6: 3-7.
  61. Boner G., Cooper M.E. Vascular endothelial growth factor-β as a determinant of diabetic nephropathy. In: Cortes P., Mogensen C.E. (eds). The diabetic kidney. Totowa, New Jersey: Humana Press. 2006. 187-200.
  62. Kim N.H., Kim K.B., Kim D.L. et al. Plasma and urinary vascular endothelial growth factor and diabetic nephropathy in Type 2 diabetes mellitus. Diabet. Med. 2004; 21: 545-551.
  63. Hohenstein B., Hausknecht B., Boehmer K. et al. Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man. Kidney Int. 2006; 69: 1654-1661.
  64. Fornoni A., Ijaz A., Tejada T., Lenz O. Role of inflammation in diabetic nephropathy. Curr. Diabetes Rev. 2008; 4: 10-17.
  65. Бондарь И.А., Климонтов В.В. Патогенез диабетической нефропатии. Иммуновоспалительные факторы. В: Шестакова М.В., Дедов И.И. (ред.). Сахарный диабет и хроническая болезнь почек. М.: Медицинское информационное агентство. 2009. 109-118.
  66. Wong C.K., Ho A.W., Tong P.C. et al. Aberrant activation profile of cytokines and mitogen-activated protein kinases in type 2 diabetic patients with nephropathy. Clin. Exp. Immunol. 2007; 149: 123-131.
  67. Goldberg R.B. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J. Clin. Endocrinol. Metab. 2009; 94: 3171-3182.
  68. Chow F., Ozols E., Nikolic-Paterson D. J. et al. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int. 2004; 65: 116-128.
  69. Yonemoto S., Machiguchi T., Nomura K. et al. Correlations of tissue macrophages and cytoskeletal protein expression with renal fibrosis in patients with diabetes mellitus. Clin. Exp. Nephrol. 2006; 10: 186-192.
  70. Ruster C., Wolf G. The role of chemokines and chemokine receptors in diabetic nephropathy. Front. Biosci. 2008; 13: 944-955.
  71. Banba N., Nakamura T., Matsumura M. et al. Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int. 2000; 58: 684-690.
  72. Wang Q.Y., Chen F.Q. Clinical significance and different levels of urinary monocyte chemoattractant protein-1 in type 2 diabetes mellitus. Diabetes Res. Clin. Pract. 2009; 83: 215-219.
  73. Mezzano S., Droguett A., Burgos M.E. et al. Renin-angiotensin system activation and interstitial inflammation in human diabetic nephropathy. Kidney Int. Suppl. 2003; 86: S64-S70.
  74. Mezzano S., Aros C., Droguett A. et al. NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol. Dial. Transplant. 2004; 19: 2505-2512.
  75. Saito T., Urushihara M., Kotani Y. et al. Increased urinary angiotensinogen is precedent to increased urinary albumin in patients with type 1 diabetes. Am. J. Med. Sci. 2009; 338: 478-80.
  76. Pätäri A., Forsblom C., Havana M. et al. Nephrinuria in diabetic nephropathy of type 1 diabetes. Diabetes. 2003; 52: 2969-2974.
  77. Wang G., Lai F.M., Lai K.B. et al. Urinary messenger RNA expression of podocyte-associated molecules in patients with diabetic nephropathy treated by angiotensin-converting enzyme inhibitor and angiotensin receptor blocker. Eur. J. Endocrinol. 2008; 158: 317-322.
  78. Rossing K., Mischak H., Dakna M. et al. Urinary proteomics in diabetes and CKD. Am. Soc. Nephrol. 2008; 19: 1283-1290.
  79. Merchant M.L., Perkins B.A., Boratyn G.M. et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J. Am. Soc. Nephrol. 2009; 20: 2065-2074.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать